Effects of PPARγ Agonist Pioglitazone on Redox-Sensitive Cellular Signaling in Young Spontaneously Hypertensive Rats

Ima Dovinová, 1 Miroslav Barancik, 2 Miroslava Majzunova, 1 Stefan Zorad, 3 Lucia Gajdosechová, 2 Linda Gresová, 1 Sona Cacanyiova, 1 Frantisek Kristek, 1 Peter Balis, 1 and Julie Y. H. Chan 4

1 Institute of Normal and Pathological Physiology, SAS, Sienkiewiczova 1, 813 71 Bratislava, Slovakia
2 Institute for Heart Research, SAS, Dubravska cesta 9, 840 05 Bratislava, Slovakia
3 Institute of Experimental Endocrinology, SAS, Vlarska 3, 833 06 Bratislava, Slovakia
4 Center for Translational Research in Biomedical Science, Kaohsiung Chang Gang Memorial Hospital, 123 Ta Pei Road, Kaohsiung 83301, Taiwan

Correspondence should be addressed to Ima Dovinová; ima.dovinova@savba.sk

Received 26 July 2013; Revised 17 October 2013; Accepted 6 November 2013

Academic Editor: Nanping Wang

Copyright © 2013 Ima Dovinová et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PPARγ receptor plays an important role in oxidative stress response. Its agonists can influence vascular contractility in experimental hypertension. Our study was focused on the effects of a PPARγ agonist pioglitazone (PIO) on blood pressure regulation, vasoactivity of vessels, and redox-sensitive signaling at the central (brainstem, BS) and peripheral (left ventricle, LV) levels in young prehypertensive rats. 5-week-old SHR were treated either with PIO (10 mg/kg/day, 2 weeks) or with saline using gastric gavage. Administration of PIO significantly slowed down blood pressure increase and improved lipid profile and aortic relaxation after insulin stimulation. A significant increase in PPARγ expression was found only in BS, not in LV. PIO treatment did not influence NOS changes, but had tissue-dependent effect on SOD regulation and increased SOD activity, observed in LV. The treatment with PIO differentially affected also the levels of other intracellular signaling components: Akt kinase increased in the BS, while β-catenin level was down-regulated in the BS and up-regulated in the LV. We found that the lowering of blood pressure in young SHR can be connected with insulin sensitivity of vessels and that β-catenin and SOD levels are important agents mediating PIO effects in the BS and LV.

1. Introduction

Blood pressure is regulated by several internal systems. Power-spectral analysis identifies oscillations in heart rate and blood pressure that are modulated by inputs from the renin-angiotensin system, sympathetic and parasympathetic neurons, and locally released vasoactive factors such as nitric oxide (NO). Current findings support the view that the reactive oxygen species (ROS) and antioxidant enzymes such as superoxide dismutase (SOD) expressed in the central nervous system (CNS) play an important role in the regulation of blood pressure, and perturbations in redox homeostasis contribute to pathogenesis of hypertension [1]. Activity of ROS sources (such as NADPH oxidases), stimulated through angiotensin II system and AT1 receptors are involved in redox-sensitive intracellular signaling modulated by kinase cascades and transcriptional factors in cardiovascular system [2]. Antioxidant response and the potential sites of internal antioxidants of different SOD isoforms, could modulate blood pressure in the vasculature, the brain, and the kidney [1, 2].

The peroxisome proliferator-activated receptor γ (PPARγ) is a nuclear receptor that takes part in the regulation of lipid metabolism and in cellular signaling. Dysregulation in the PPARγ activity may underlie diseases connected with the metabolic syndrome and hypertension. As a nuclear receptor, PPARγ acts together with another nuclear receptor, the retinoid X receptor, to dissociate corepressor and recruitment of coactivator protein, which, in turn, promotes transcription of the downstream target genes involved
in adipocyte differentiation, glucose homeostasis, lipid trafficking, or anti-inflammatory response [3]. The activity of PPARγ is influenced by a variety of extracellular ligands: glitazones (rosiglitazone, pioglitazone, and troglitazone) and intracellular ligands: prostaglandins, leukotrienes, and α-lipoic acid [4].

Studies of PPARγ document a larger increase in blood pressure in endothelial PPARγ null mice in response to angiotensin II infusion [5]. This effect is connected with impaired vascular relaxation in response to acetylcholine combined with unaltered relaxation in response to sodium nitroprusside. These findings indicate that endothelial PPARγ regulates vascular NO production and that the disruption of endothelial PPARγ contributes to endothelial dysfunction in vivo. Oral intake of rosiglitazone (RSG) resulted in vasodepression and reduction of the augmented sympathetic vasomotor activity in the spontaneously hypertensive rat [6]. Overexpression of PPARγ and amelioration of oxidative stress in the brainstem rostral ventrolateral medulla (RVLM), where sympathetic promoter neurons reside, underlies the cardiovascular protective action of RSG. A recent study showed different effects of RSG application in young versus adult SHR. While in young SHR this PPARγ agonist influences PI3K/Akt/NO signaling in blood vessels through deactivation of the insulin resistance pathway, this effect was not evident in adult animals [7]. These observations open the possibility of differential effects of the PPARγ agonist in cellular signaling involved in development of hypertension in SHR of different ages.

Application of the PPARγ agonist pioglitazone (PIO) was found to influence the vascular contractility of blood vessels in SHR [8]. Several recent studies also demonstrated the implication of PPARγ in oxidative stress responses and in the imbalances between pro-oxidant and antioxidant responses that influence apoptotic or necrotic cell death [3]. PPARγ may directly modulate activation of several antioxidants involved in oxidative stress, such as the mitochondrial manganese SOD (MnSOD) [9], mitochondrial uncoupling protein (UCP2) [6], or catalase [10, 11]. This modulation was observed in several kinds of cells including cardiomyocytes [9], neuronal cells [6], adipocytes, and endothelial cells [10, 11]. The PPARγ modulation also plays a role in the isoform-specific modulation of expression of NO synthases (NOSs). PPARγ ligands promoted expression of endothelial NOS (eNOS) in vivo [5], but down-regulated the inducible NOS (iNOS) isoform [12, 13]. Moreover, the effects of PPARγ ligands were found to be connected with downregulation of the inducible cyclooxygenase-2 (COX-2) [12].

In the regulation of cellular response, the modulation of these enzyme systems is associated with several signaling pathways, such as Nrf2 (antioxidant pathway), Wnt/β-catenin (antioxidant pathway), or NF-κB (proinflammatory pathway) [3]. Several studies have shown the modulation of Akt kinase phosphorylation by PIO [14–17]. PIO was found to increase Akt phosphorylation (activation) [14, 15], but in some cell types also the inhibition or reduction of Akt-1 activity by PPARγ agonists has been observed [16, 17]. Recently, it was reported that the protein whose function could be regulated by Akt kinase-mediated phosphorylation at Ser552 is β-catenin [18]. Under normal cellular conditions, β-catenin acting through Wnt signaling is involved in cell proliferation and differentiation, but under changed ROS conditions, its function can shift to regulate the transcription factors that support cell survival through increased stress resistance and ROS clearance [19]. This suggests that β-catenin can play a pivotal role in the re-programming of the transcriptional activity in response to changes in ROS [19].

Arterial blood pressure can be influenced through several main regulatory systems located in different organs and tissues: brain (mainly in brainstem), heart (ventricles), large and small vessels (such as aorta and mesentery artery), and kidney (juxtaglomerular apparatus). In several studies, the effects of PPAR gamma on blood pressure have been studied. However, these studies did not focus on redox cellular signaling in the heart and only few results were obtained in the brain [6]. Therefore, our study was focused on the investigation of PPARγ agonist PIO on blood pressure regulation in young prehypertensive rats (SHR) and on redox-sensitive cellular signaling within systems of central (brainstem) and peripheral (left ventricle) regulation of blood pressure.

The concrete aims of this study included the determination of PIO effects on

(1) blood pressure modulation, lipid profile, adipocytes RAS components, and vessel responses,

(2) different components of redox-sensitive intracellular signaling (SOD, NOS, Akt kinase, and β-catenin) in the brainstem and in the left ventricle.

2. Materials and Methods

2.1. Experimental Model and Treatment Protocol. Young male spontaneously hypertensive rats (SHR; 5 weeks old, n = 7) were treated with PPARγ agonist pioglitazone (PIO), in the dose of 10 mg/kg/day. PIO was dissolved in saline and administered orally by gavage as a suspension during 2 weeks. Animals of the control group (n = 7) were gavaged daily with physiological solution (saline). The body weight, daily food intake, and tap water intake were measured before, during, and after the two week treatment period. All animal experiments were performed in accordance with the rules of the State Veterinary Administration of the Slovak Republic and with the guidelines of the Animal Research and Care Committee of the Institute of Normal and Pathological Physiology of the Slovak Academy of Sciences.

2.2. Blood Pressure Determination. Systolic blood pressure was measured noninvasively by tail cuff plethysmography in both the control and PIO-treated groups of rats. Blood pressure measurements were performed on days 1, 5, 9, and 12 of the treatment period.

2.3. Collection of Samples. At the end of the experiment, the animals were sacrificed and hearts and brain were rapidly excised. Aorta was also isolated and used for further
Table 1: Primer pairs used for amplification of selected genes.

| Gene       | Forward (sense) primer | Reverse (antisense) primer | Amplicon size (bp) | Temp (°C) |
|------------|------------------------|----------------------------|--------------------|-----------|
| SOD1       | CACTCTAAGAAAATGGCG     | CTGAGTGAGTACAACG           | 124                | 54        |
| SOD2       | TTCAGCTGACCTGAAAG      | GTCACGCTGAGTACCTC          | 122                | 54        |
| SOD3       | CTTGACCTGGTATGAGAATA   | GATCTGTGGATGCTACG          | 154                | 58        |
| NOS3       | CCACTACGTGGTCTAAGCA    | TCACTCACGAGCTTTCCA         | 124                | 57        |
| NOS1       | CCGTACGCTGGTAAAGAG    | GCTTCATGAGAAGTTCA          | 118                | 60        |
| GAPDH      | TGGAGGTGCTGGAAGTTTCCAT | CTGACGCTTGGATGCTAGC        | 120                | 60        |
| p22phox    | CAGCACTGTACCCTGTGCTA  | TTGACGTCTGCTGGGTTCA        | 170                | 60        |
| ACE        | ATGGTACAGAAGGGCTGGA    | TTGTAGAAGTCCCACGCA         | 170                | 60        |
| AGT        | CATGAGTTCTGGTTGGACA    | AAGTTGTTGGGGTTGCA          | 95                 | 60        |
| AT1R       | TCTCAGCATCGATCGCTACCT | AGGCAGACTTCATTGGGTA        | 51                 | 60        |
| aP2 (FABP4)| AGCGAGGAACGGATGCTTG    | ATGGTGCTGACCTTTCCATG       | 185                | 60        |
| PPARγ      | AGGATTGATAGAAGGGGTA    | GCAGATCTGAAAGTTTTCTGAA    | 79                 | 60        |
| RPS29      | GCTGAACTGTCGGACACAT    | GCTGAGGATGCTTCAATGAA       | 74                 | 60        |
| UCP-1      | GCCTCTACGATAGCCCTG    | TGCATTGACCTTTACCACC       | 145                | 60        |

Functional studies. Excised hearts were weighed, and left and right ventricles were separated. The whole heart and ventricular weights were registered. Further processing of tissue samples depended on the specific assay. For measurement of superoxide levels, tissues were collected into ice-cold Krebs buffer. For measurements of NOS and SOD activities, the tissue samples were cooled in Tris-HCl supplemented with a protease inhibitor cocktail and further processed according to individual methods. The tissue samples for molecular-biological (qPCR) and biochemical (Western blot) analyses were frozen in liquid nitrogen and stored at −80 °C until further use.

Plasma samples were prepared from whole blood collected into Na-EDTA solution. After centrifugation for 5 min at 1200 × g, the plasma was collected. Prepared plasma samples were stored at −80 °C until further analysis.

2.4. Functional Studies In Vitro. Thoracic aorta was isolated, cleaned of connective tissue, and cut into rings (4 mm in length). The rings were fixed between two stainless wire triangles in an incubation organ bath containing Krebs solution (NaCl 118 mM, KCl 5 mM, NaHCO₃ 25 mM, MgSO₄ 1.2 mM, KH₂PO₄ 1.2 mM, CaCl₂ 2.5 mM, glucose 11 mM, CaNa₂EDTA 0.032 mM). The solution was oxygenated with pneumox (95% O₂, 5% CO₂) at 37°C. The upper wire triangles were connected to electromechanical transducers (Experimetria) and the changes in isometric tension were registered using AD converter and Dewetron software. The resting tension was adjusted to 1 g and applied to each ring.

Subsequently, preparations were equilibrated for 60 minutes and the presence of functional endothelium was assessed in all preparations. Contractile responses induced by KCl (100 mmol/L) were used to achieve receptor-independent maximal contraction. The relaxant responses were followed on rings precontracted with noradrenaline (10⁻⁶ mol/L) to produce a stable plateau of contraction. The rings were then exposed to acetylcholine (10⁻⁵ mol/L) or insulin (10⁻⁶ mol/L) to induce a maximal response. Relaxation was expressed as a percentage of noradrenaline-induced contraction.

2.5. Gene Expression Determination. Total RNA from the brainstem and left ventricle tissue samples was isolated with TRIzole reagent (Bioline) according to the manufacturer’s protocol. Total RNA from adipose tissue was isolated by RNeasy Universal Plus Mini Kit (Qiagen). The isolated total RNA was quantified spectrophotometrically at 260/280 nm using Nanodrop. Reverse transcription (RT) reaction was performed using TetrocDNA kit (Bioline) on Eppendorf Mastercycler.

Real-time polymerase chain reaction (qPCR) by amplification of cDNA was performed on a Biorad CFX96 Real-time system using the SensiFAST SYBR No ROX kit (Bioline). PCR reaction for each sample was carried out in duplicate for all cDNA and for the housekeeping gene of glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

The primer pairs used for amplification of studied genes (PPARγ, SOD1, SOD2, SOD3, NOS1, NOS3, p22phox, AT1R, UCP-1, AGT, ACE, aP2, GAPDH, and RPS29) are listed in Table 1.

2.6. Determination of Total Superoxide Dismutase and Nitric Oxide Synthase Activities. The total superoxide dismutase (SOD) activity was analyzed using the SOD Assay kit (Fluka) in tissue samples. The rate of WST-1 reduction with superoxide is linearly related to the xanthine oxidase activity, and is inhibited by SOD. The SOD activity was determined as an inhibition activity by measuring the color decrease of WST-1-formazan production at 450 nm (Thermo Scientific Multiscan FC).

Total activity of nitric oxide synthases (NOSs) was determined using measurement of the conversion of radioactive ³H-L-Arginine to ³H-L-Citrulline [20] and the product was
detected by liquid scintillator Tri-Carb 2910 TR (Perkin Elmer).

2.7. Electrophoresis and Immunochemical Western Blot Analysis. Samples of protein fractions containing equivalent amounts of proteins per lane were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). After electrophoretic separation, proteins were transferred to a nitrocellulose membrane. The quality of the transfer was controlled by Ponceau S staining of nitrocellulose membranes after the transfer and protein loading by using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a housekeeper. Specific anti-SOD1, anti-SOD2, anti-Akt kinase, anti-β-catenin, anti-GAPDH (all from Santa Cruz Biotechnology), and anti-phospho-Akt kinase (Ser473 and Thr308) (from Cell Signaling Technology) antibodies were used for the primary immunodetection. Peroxidase-labelled anti-rabbit immunoglobulin (Cell Signaling Technology) was used as the secondary antibody. Bound antibodies were detected by the enhanced chemiluminescence (ECL) detection method.

2.8. Lipid Profile, Glucose and Insulin Level Determination. Plasma insulin levels were evaluated by RIA kits (Milli-pore) following the manufacturer’s protocol. Lipid profile and blood glucose determinations were done at Synlab (Bratislava, Slovakia) using the COBAS Integra 800 multianalyzer (Roche).

2.9. Statistical Evaluation. The data for blood pressure measurements were evaluated using a two-way ANOVA and for in vitro functional studies using a one-way ANOVA with Bonferroni adjustment in post hoc tests. Data from other measurements were analyzed either by the Student’s t-test or the Wilcoxon-Mann-Whitney U-test. Differences were considered significant at $P < 0.05$ in all tests.

3. Results

3.1. Blood Pressure and General Physiological Parameters. The blood pressure in young SHR significantly increased from 113 mmHg to 151 mmHg between the 5th and 7th week of age. Administration of the PPARγ agonist PIO significantly slowed down the development of blood pressure increase in young prehypertensive animals (Figure 1).

The effects of PIO treatment on rat body weight, heart weight, the weights of the left (LV) and the right (RV) ventricles, and plasma insulin and glucose concentrations were measured and determined. The body weight and weight of the total cardiac mass were not changed significantly in PIO-treated rats. In addition, the ratios of the weights of the whole heart or ventricles versus body weight were not influenced by PIO. In young SHR treated with PIO, we observed a slightly increased weight of epididymal fat (control group: 0.31 ± 0.04 g; PIO group: 0.38 ± 0.03 g) and adiposity index (control group: 0.26 ± 0.04%; PIO group: 0.32 ± 0.02%), but these changes were not statistically significant. The treatment

![Figure 1: Effect of pioglitazone (PIO) administration on blood pressure of young SHRs. Blood pressure was measured using the plethysmography tail-cuff method on days 1, 5, 9, and 12 of the treatment period. The data represent mean ± SEM, $n = 7$. ∗ $P < 0.05$, PIO versus control.](image)

| Table 2: Vasoactive responses influenced by PIO treatment on relaxation and contraction of thoracic aorta. |
|---------------------------------|---------------------------------|---------------------------------|
|                                | n Control group | n PIO-treated group |
| Ach (10⁻⁶ mol/L)                | 10 76.89 ± 6.85% | 14 75.67 ± 5.8% |
| Ins (10⁻⁶ mol/L)                | 8 6.81 ± 2.43%  | 11 20.29 ± 2.48%** |
| NA (10⁻⁸ mol/L)                 | 8 0.18 ± 0.04 g | 15 0.24 ± 0.03 g |
| KCl (100 mmol/L)               | 11 0.98 ± 0.05 g | 8 0.96 ± 0.03 g |

Ach: acetylcholine; Ins: insulin; NA: noradrenaline; KCl: potassium chloride; ** $P < 0.01$ PIO versus control group.

also did not significantly influence the plasma concentrations of insulin and glucose.

3.2. Vasoactivity of Vessels. In functional in vitro studies, we investigated the vasoactivity of aorta rings in the control and PIO-treated groups of young SHR (Table 2). Maximal relaxation of aorta was observed either after acetylcholine (Ach) or insulin (Ins) stimulation. Endothelium-dependent relaxation to Ach did not differ between groups. We observed small relaxation response to Ins in both groups; however, the maximal response to Ins was significantly higher in the PIO-treated group compared to control group ($P < 0.01$). Contractile responses induced by stimulation of adrenergic receptors (noradrenaline) as well as by depolarisation (KCl) were similar in both groups.

3.3. Effect of Pioglitazone Administration on Changes in Lipid Profile. The observed effects of PIO on modulation of blood pressure and functional properties of vessel vasoactivity (relaxation of thoracic aorta) could reflect also changes in circulating lipids. We observed that pioglitazone treatment affected the plasma lipid profile in our young SHR. Total cholesterol concentration was significantly reduced after PIO
treatment (Figure 2) and, due to the total cholesterol reduction, also HDL and LDL were significantly reduced (actually, LDL/HDL and cholesterol/HDL ratios were unchanged). Plasma triglycerides and VLDL were not influenced by the pioglitazone treatment.

3.4. Gene Expression in Adipose Tissues. mRNA expression of PPARγ and AP2, markers of adipogenesis, was not changed by pioglitazone. When analyzing the mRNA of selected components of local adipose tissue RAS (AGT, ACE, and AT1 receptors), only the AT1 receptor was found significantly elevated. Gene expression of UCP1 tended to increase under pioglitazone treatment (Figure 3).

PPARγ: peroxisome proliferator-activated receptor; AT1R: angiotensin-1 receptor; aP2: adipose fatty acid-binding protein; UCP1: uncoupling protein-1; AGT: angiotensinogen; ACE: angiotensin converting enzyme. Data represent mean ± SEM, n = 7. *P < 0.05, PIO versus control.

3.5. Effect of Pioglitazone on PPARγ Expression in the Left Ventricle and Brainstem. In the brainstem of the PIO-treated animals, we observed a significant increase in mRNA encoding PPARγ. In the LV, we observed no change relative to control (Figure 4).

3.6. ROS Activation, Antioxidant Response, and SOD/NOS Balance in the Left Ventricle and Brainstem. Our study was focused also on the effects of PIO on enzymes involved in the regulation of ROS levels (p22phox subunit of NADPH oxidase system and SOD), and we observed different responses in the brainstem and the left ventricle. We found tissue-specific changes in the expression of genes involved in radical signaling, AT1R, and p22phox. PIO treatment modulated the expression of AT1R and p22phox only in the brainstem and induced moderate increase in their mRNA levels (by 34% for AT1R and by 20% for p22phox).

Antioxidant response of SOD genes and SOD/NOS balance in the left ventricle and brainstem were investigated using a study of expression of individual SOD or NOS isoforms and by determination of their total activities. In the left ventricle, we observed no change in the expression of the SOD1 (Table 3) or SOD3 (not shown) isoforms. Significant changes were found only for the expression of mRNA encoding SOD2. In the brainstem, the increase of PPARγ mRNA was accompanied with the upregulation of SOD2 and downregulation of SOD1 mRNA expression (Table 3). Similar to the left ventricle, the expression of SOD3 was unchanged (not shown).
PIO treatment revealed different, tissue-specific effects on SOD activities. In the left ventricle, PIO induced a significant increase of total SOD activity, while no change was observed in the brainstem (Figure 5(d)). The observed increase in the total SOD activities in the left ventricle has been found to be connected with partial (nonsignificant) upregulation of SOD2 protein levels (Figures 5(a) and 5(c)). Similar changes in SOD2 protein levels were found in the brainstem (Figures 5(b) and 5(c)). Levels of the SOD1 isoform were not changed neither in LV nor in BS (Figures 5(a) and 5(b)).

For NOS isoforms, the only significant effect of PIO treatment was observed for NOS1 (nNOS), a decrease in the brainstem (Figure 6(a)). The treatment did not influence the total NOS activities in the left ventricle or in the brainstem (Figure 6(b)).

3.7 Effect of Pioglitazone on Regulatory Proteins Involved in Redox Signaling. The influence of PIO on Akt kinase and β-catenin, components of two distinct redox-sensitive signaling kinase pathways (PI3K/Akt and Wnt/β-catenin), was studied in tissue samples of the left ventricle and brainstem. Our data show that PIO induced increase in protein levels ofAkt kinase in brainstem (Figures 7(b) and 7(c)), but not in the left ventricle (Figures 7(a) and 7(c)). Using antibodies specific for detection of Akt kinase phosphorylated specifically at Ser473 or Thr308, we looked also for changes in activation of the enzyme. However, the actions of PIO observed in the brainstem were not connected with modulation of specific Ser473 or Thr308, we looked also for changes in activation of the enzyme. While in the brainstem we obtained an increase in the gene, in the left ventricle the levels significantly increased (Figures 7(b) and 7(d)), while in the brainstem, we observed a significant decrease (Figures 7(b) and 7(d)). Protein loading was controlled by using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and we did not observe any differences.

4. Discussion

The development of hypertension can be induced by various stimuli and is associated with several changes in the radical and antioxidant responses as well as in cellular signaling. In the present study, we investigated the effects of PPARγ agonist pioglitazone during hypertension development in young SHR. Our study focused on PIO-induced changes in the brainstem (CNS level) and the left ventricle of the heart (peripheral level) on blood pressure regulation. Moreover, the effects of PIO on changes in overall lipids and adipocytes during hypertension development in young SHR were determined.

Table 3: mRNA expression of SOD1 and SOD2 isoforms after PIO treatment.

| mRNA         | Control Left ventricle | PIO Left ventricle | Control Brainstem | PIO Brainstem |
|--------------|------------------------|--------------------|-------------------|--------------|
| SOD1/GAPDH   | 1.46 ± 0.115           | 1.30 ± 0.087       | 1.39 ± 0.247      | 0.75 ± 0.099*|
| SOD2/GAPDH   | 1.20 ± 0.107           | 0.85 ± 0.075*      | 0.97 ± 0.067      | 1.24 ± 0.078*|

Data represent mean ± SEM, *P < 0.05, PIO versus control.

PPARγ agonists are substances used as insulin sensitizers in diabetic patients with or without hypertension [21]. Administration of PIO to young SHR in our study retarded the blood pressure development. Several studies using RSG confirmed the blood pressure lowering effect of this PPARγ agonist in experimental hypertension [6, 7]. The effects of RSG observed in these studies were usually associated with changes in insulin sensitivity but without effects on glucose level. Our experimental data with PIO, another PPARγ agonist, partially contradict the findings with RSG. We observed no significant change in glucose or in plasma insulin levels after PIO treatment in young rats.

In our study, SHR were used at the age of 7 weeks, which is a period before insulin resistance is developing [22]. This was confirmed by normal glucose and insulin plasma levels in both control and PIO-treated SHR groups. In addition, plasma lipid parameters seem to be also in normal range in young SHR. However, PIO significantly reduced total plasma cholesterol by decreasing both HDL and LDL fractions. To our knowledge this is the first demonstration of PIO lipid-lowering activity in rats without dyslipidemia [23]. An explanation of the underlying mechanisms will require a study of the liver pathways of cholesterol synthesis as well as its inflammatory status in young SHR. Our in vitro studies of vessel vasoactivity showed improved vasodilatation response after insulin stimulation in the young SHR treated with PIO. These observations suggest increased insulin sensitivity in the aorta of treated animals and may have an impact on the delay of blood pressure increase. Similar to our data, also another PPAR gamma agonist rosiglitazone has been found to improve aortic vasodilatory response to insulin in SHR [7].

PPARγ mRNA expression in LV and BS was different. While in the brainstem we obtained an increase in the gene, in the left ventricle we did not observe any changes. Therefore, we suppose that the responses in the brainstem can be directly modulated through PPARγ, while in the left ventricle the regulation can be independent from PPARγ and affected by pioglitazone only. Direct and indirect effects of PPARγ agonists to the cardiac metabolism have been observed also on model of PPARγ, knockout mice [24]. It was found that at baseline conditions, PPARγ does not play a crucial role in regulating cardiac metabolism in mice. The authors suggested that it is likely due to low myocardial PPARγ expression and that agonists may protect myocardium indirectly.

Some studies documented that application of RSG can activate PI3K/Akt/NOS signaling pathway in endothelium of young SHR [7]. In our study, we investigated whether PIO can affect this signaling pathway. However, in the brainstem and the left ventricle, we did not observe significant influence of PIO on Akt kinase activation. Similar to our data obtained
Figure 5: Effect of pioglitazone administration on SOD1 and SOD2 protein levels and total SOD activities in the left ventricle and brainstem of young SHRs. (a) Western blot records documenting SOD1, SOD2, and GAPDH protein levels in fraction isolated from the tissues of the left ventricle of control and PIO-treated group. (b) Western blot records documenting SOD1, SOD2, and GAPDH protein levels in brainstem. (c) Quantification of SOD2 protein levels normalized to the GAPDH protein levels. Data were obtained from Western blot records and each bar represents mean ± SEM of 7 tissue samples per group. *P < 0.05, PIO versus control. (d) The SOD activities were analyzed using the SOD Assay kit (Fluka) in tissue samples of left ventricle and brainstem. The specific activities are expressed in units per mg of proteins and are presented as mean ± SEM, n = 7. *P < 0.05, PIO versus control.

in the left ventricle are the findings that pretreatment with PIO does not significantly increase myocardial Akt kinase phosphorylation in the rat [25]. Akt kinase expression in the brain was reported to modify food intake [26]. However, in our study, the increase in Akt kinase expression in the brainstem was not associated with significant changes in food intake and there were no differences in body weight between control and PIO-treated rats.

We also found that activities of NOS, as another component of this PI3K/Akt/NOS pathway, were not influenced by PIO. Similarly, another study showed that in an in vivo rat model, PIO alone did not cause significant increase in myocardial phospho-Akt or phospho-eNOS [25]. Several works investigated the association between PIO treatment and NO level. The cardioprotective effects of PIO during ischemia and reperfusion in myocardial ischemic injury were observed in rabbits and may depend on NO [27]. In patients with diabetes mellitus, also the effects of PIO on eNOS and iNOS were studied. In patients with insulin resistance, a significant decrease in the levels of eNOS and iNOS was observed [28]. On the other hand, these changes in NOS isoforms were not found in patients without developed insulin
resistance. Our results show that NOS isoforms were not changed in the LV, while only the nNOS isoform was down-regulated in the brainstem. Moreover, PIO did not induce any change in NOS activities in young SHR. This observation may be related to the fact that no significant differences in NOS activities were observed in young hypertensive SHR and young normotensive WKY rats below 9 weeks of age. Only a tendency of a decrease in NOS activities was observed in young SHRs [29].

PIO, known as an antidiabetic agent with antioxidant and anti-inflammatory effects against oxidative stress conditions [30, 31], is also suggested to reduce, directly and/or indirectly, the overproduction of ROS. Our study was focused also on the effects of PIO on the enzymes involved in the regulation of ROS levels (p22phox subunit of NADPH oxidase system, SOD) and observed different responses in the brainstem and the left ventricle. In the brainstem, where the effects of PIO were connected to upregulation of PPAR\textsubscript{\&}\textgreek{a}, we found also a borderline increase in AT1 receptor, p22phox, and significant upregulation of the SOD2 isoform. The observed SOD2 upregulation is in agreement with promoter analysis showing that gene of this mitochondrial SOD isoform can be a direct target of PPAR\textsubscript{\&}\textgreek{a} [9]. However, total SOD activities were not influenced in the brainstem. On the other hand, there were no observable changes in AT1 receptor and p22phox in the left ventricle, and the effects of PIO were not joined directly with PPAR\textsubscript{\&}\textgreek{a} overexpression. In contrast to the brainstem, we observed antioxidant effects of PIO treatment in the left ventricle realized through an increase in total SOD activities. Tissue-specific differences in response to pioglitazone were observed also for \&-catenin. Several studies have demonstrated a direct connection between PPAR\textsubscript{\&}\textgreek{a} signaling and \&-catenin pathway [32–35]. Moreover, it has been shown that interaction between PPAR\textsubscript{\&}\textgreek{a} and \&-catenin promotes regulation of genes that confer normal function and homeostasis to vascular cells [33]. \&-catenin is a protein acting through Wnt signaling and under changed ROS conditions acting as a regulator of the transcription factors that support cell survival through increased stress resistance and ROS clearance [19]. The observed different effects of PIO on proteins involved in redox signaling at central and peripheral level should be clarified by further investigation.

Pioglitazone induces adipogenesis \textit{in vitro} on 3T3L1 adipocyte culture [36]. \textit{In vivo} RSG was shown to induce adipogenesis in subcutaneous adipose tissue [37] and this effect seems to be depot-specific [38]. In our experiment, PIO did not influence expression of PPAR\textsubscript{\&}\textgreek{a} and AP2, markers of adipogenesis, in epididymal adipose tissue. Thus, we conclude that stimulation of PPAR\textsubscript{\&}\textgreek{a} in young SHR under our experimental conditions does not lead to alternation of adipose tissue structure and mass. It has been shown that RSG decreases both angiotensinogen protein expression and angiotensin II release in isolated human subcutaneous adipocytes [39]. In addition, it was reported that PIO treatment decreases serum angiotensin II level in type 2 diabetes patients [40]. The above facts lead us to study the expression of adipose tissue RAS components under PIO treatment. Angiotensinogen and ACE mRNA in epididymal adipose tissue were not influenced by PIO, but AT1 receptor expression was significantly up-regulated. Since PIO retards the development of high blood pressure in young SHR, we hypothesize that the reduced serum angiotensin II might be involved in the mechanisms of this blood-reducing effect. Despite the absence of data on serum angiotensin II, we
speculate that the upregulation of AT1 receptor expression is a physiological response to decreased serum angiotensin II.

5. Conclusion

Our results show that the treatment of young SHRs with PIO retards high blood pressure development, and this effect is associated with an improvement of lipid profile (CHOL, LDL) and vessel vasoreactivity, without changes in glucose and insulin plasma levels, and with some changes in adipocyte RAS components. The treatment also differentially affects the redox-sensitive intracellular signaling (SOD, NOS, Akt kinase, and β-catenin) in the brainstem and in the heart. Lowering of blood pressure in young SHR can be directly affected by vessel vasorelaxation stimulated by insulin, and our data suggest that β-catenin and antioxidant SOD response, but not NOS, can be important agents of PIO effects in the brainstem and the left ventricle of young prehypertensive rats.

Acknowledgments

The authors would like to thank Maria Fagarassyova, Antonia Koplikova, and Lucia Kovacovicova for their excellent technical assistance and Peter Kvasnicka for assistance.
in manuscript preparation. This study was supported by Grants SAS-NSC JRP 2010/01, NSC100-2923-B075B-001-MY3 (JYHC), APVV-0348-12, VEGA SR 2/0169/12, and VEGA SR 2/0089/11.

References

[1] H. E. Loh, P. J. Marvar, T. J. Guzik et al., "Induction of hypertension and peripheral inflammation by reduction of extracellular superoxide dismutase in the central nervous system," Hypertension, vol. 55, no. 2, pp. 277–283, 2010.

[2] M. Majzunova, I. Dovinova, M. Barancik, and J. Y. Chan, "Redox signaling in pathophysiology of hypertension," Journal of Biomedical Science, vol. 20, no. 1, pp. 1, 69, 2013.

[3] M. Collino, M. Aragno, S. Castiglia et al., "Pioglitazone protects the heart via activation of PPAR-γ receptors, P3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction," American Journal of Physiology, vol. 296, no. 5, pp. H1558–H1565, 2009.

[4] S. Polvani, M. Tarocchi, and A. Galli, "PPAR and oxidative stress: Con(β) catenating NRF2 and FOXO," PPAR Research, vol. 2012, Article ID 641087, 15 pages, 2012.

[5] K. L. Housekencht, B. M. Cole, and P. J. Steele, "Peroxisome proliferator-activated receptor gamma (PPARY) and its ligands: a review," Domestic Animal Endocrinology, vol. 22, no. 1, pp. 1–23, 2002.

[6] J. M. Kleinhenz, D. J. Kleinhenz, S. You et al., "Disruption of endothelial peroxisome proliferator-activated receptor-γ reduces vascular nitric oxide production," American Journal of Physiology, vol. 297, no. 5, pp. H1647–H1654, 2009.

[7] S. H. H. Chan, K. L. H. Wu, P. S. S. Kung, and J. Y. H. Chan, "Oral intake of rosiglitazone promotes a central antihypertensive effect via upregulation of peroxisome proliferator-activated receptor-γ and alleviation of oxidative stress in rostral ventrolateral medulla of spontaneously hypertensive rats," Hypertension, vol. 55, no. 6, pp. 1444–1453, 2010.

[8] R. Li, H. Zhang, W. Wang et al., "Vascular insulin resistance in prehypertensive rats: role of P3-kinase/Akt/eNOS signaling," European Journal of Pharmacology, vol. 628, no. 1–3, pp. 140–147, 2010.

[9] D. Hao, N. Ning, G. Hao, and X. Niu, "Pioglitazone attenuates vascular fibrosis in spontaneously hypertensive rats," PPAR Research, vol. 2012, Article ID 856426, 7 pages, 2012.

[10] G. Ding, M. Fu, Q. Qin et al., "Cardiac peroxisome proliferator-activated receptor γ is essential in protecting cardiomyocytes from oxidative damage," Cardiovascular Research, vol. 76, no. 2, pp. 269–279, 2007.

[11] Y. Okuno, M. Matsuda, Y. Miyata et al., "Human catalase gene is regulated by peroxisome proliferator-activated receptor-gamma through a response element distinct from that of mouse," Endocrine journal, vol. 57, no. 4, pp. 303–309, 2010.

[12] G. D. Gurnun, F. E. Domann, S. A. Moore, and M. E. C. Robbins, "Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter," Molecular Endocrinology, vol. 16, no. 12, pp. 2793–2801, 2002.

[13] Y. Zhao, A. Patzer, T. Herdegen, P. Gohlke, and J. Culman, "Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats," The FASEB Journal, vol. 20, no. 8, pp. 1162–1175, 2006.

[14] M. Collino, M. Aragno, R. Mastrocola et al., "Modulation of the oxidative stress and inflammatory response by PPAR-γ agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion," European Journal of Pharmacology, vol. 530, no. 1-2, pp. 70–80, 2006.

[15] Y. Birnbaum, B. Long, J. Qian, J. R. Perez-Polo, and Y. Ye, "Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-γ-independent manner," Basic Research in Cardiology, vol. 106, no. 3, pp. 431–446, 2011.

[16] S. Yasuda, H. Kobayashi, M. Iwasa et al., "Antidiabetic drug pioglitazone protects the heart via activation of PPAR-γ receptors, P3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction," American Journal of Physiology, vol. 296, no. 5, pp. H1558–H1565, 2009.

[17] S. Goetze, F. Eilers, A. Bungenstock et al., "PPAR activators inhibit endothelial cell migration by targeting Akt," Biochemical and Biophysical Research Communications, vol. 293, no. 5, pp. 1431–1437, 2002.

[18] Y. Xiao, T. Yuan, W. Yao, and K. Liao, "3T3-L1 adipocyte apoptosis induced by thiazolidinediones is peroxisome proliferator-activated receptor-γ-dependent and mediated by the caspase-3-dependent apoptotic pathway," FEBS Journal, vol. 277, no. 3, pp. 687–696, 2010.

[19] D. Fang, D. Hawke, Y. Zheng et al., "Phosphorylation of β-catenin by AKT promotes β-catenin transcriptional activity," Journal of Biological Chemistry, vol. 282, no. 15, pp. 11221–11229, 2007.

[20] D. Hoogeboom and B. M. T. Burgering, "Should I stay or should I go: β-catenin decides under stress," Biochimica et Biophysica Acta, vol. 1796, no. 2, pp. 63–74, 2009.

[21] J. Kopincová, A. Púszserová, and I. Bernátová, "Chronic low-dose L-NAME treatment effect on cardiovascular system of borderline hypertensive rats: feedback regulation?" Neuroendo- crinology Letters, vol. 29, no. 5, pp. 784–789, 2008.

[22] M. Sharogradsky, K. Michaelova, M. Boaz, D. Gavish, and R. Zimlichman, "Effect of long-term treatment with rosiglitazone on arterial elasticity and metabolic parameters in patients with type 2 diabetes mellitus: a 2-year follow-up study," Diabetic Medicine, vol. 24, no. 11, pp. 1254–1260, 2007.

[23] M. Pravenec, V. Zídek, V. Landa et al., "Age-related autocrine diabetogenic effects of transgenic resistin in spontaneously hypertensive rats: gene expression profile analysis," Physiological Genomics, vol. 43, no. 7, pp. 372–379, 2011.

[24] M. Collino, M. Aragno, S. Castiglia et al., "Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation," British Journal of Pharmacology, vol. 160, no. 8, pp. 1892–1902, 2010.

[25] M. Barbieri, C. Di Filippo, A. Esposito et al., "Effects of PPARs agonists on cardiac metabolism in littermate and cardiomyocyte-specific PPAR-γ -knockout (CM-PGKO) mice," PLoS ONE, vol. 7, no. 4, Article ID e53999, 2012.

[26] Y. Ye, Y. Lin, S. Atar et al., "Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions," American Journal of Physiology, vol. 291, no. 3, pp. H1158–H1169, 2006.

[27] D. H. Kim, S. C. Woods, and R. J. Seeley, "Hypothalamic Akt/PKB signaling in regulation of food intake," PLoS Medicine, vol. 4, pp. 953–966, 2007.

[28] H. Kawabata and K. Ishikawa, "Cardioprotection with pioglitazone isabolished by nitric oxide synthase inhibitor in ischemic rabbit hearts—comparison of the effects of pioglitazone and metformin," Diabetes/Metabolism Research and Reviews, vol. 19, no. 4, pp. 299–305, 2003.
diabetes mellitus,” *Journal of the cardiometabolic syndrome*, vol. 3, no. 4, pp. 200–204, 2008.

[29] A. Kondrashov, S. Vranková, I. Dovinová et al., “The effects of new Alibernet red wine extract on nitric oxide and reactive oxygen species production in spontaneously hypertensive rats,” *Oxidative Medicine and Cellular Longevity*, vol. 2012, Article ID 806285, 8 pages, 2012.

[30] A. H. Dorafshar, K. Moodley, M. Khoo, C. Lyon, and M. Bryer-Ash, “Pioglitazone improves superoxide dismutase-mediated vascular reactivity in the obese Zucker rat,” *Diabetes and Vascular Disease Research*, vol. 7, no. 1, pp. 20–27, 2010.

[31] A. Gumieniczek, Ł. Komsta, and M. R. Chehab, “Effects of two oral antidiabetics, pioglitazone and repaglinide, on aconitase inactivation, inflammation and oxidative/nitrosative stress in tissues under alloxan-induced hyperglycemia,” *European Journal of Pharmacology*, vol. 659, no. 1, pp. 89–93, 2011.

[32] G. D. Girnun, W. M. Smith, S. Drori et al., “APC-dependent suppression of colon carcinogenesis by PPARγ,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 21, pp. 13771–13776, 2002.

[33] T.-P. Alastalo, M. Li, V. De Jesus Perez et al., “Disruption of PPARγ/β-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival,” *The Journal of Clinical Investigation*, vol. 121, no. 9, pp. 3735–3746, 2011.

[34] D. Lu and D. A. Carson, “Repression of β-catenin signaling by PPARγ ligands,” *European Journal of Pharmacology*, vol. 636, no. 1–3, pp. 198–202, 2010.

[35] C. Sharma, A. Pradeep, L. Wong, A. Rana, and B. Rana, “Peroxisome proliferator-activated receptor γ activation can regulate β-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway,” *Journal of Biological Chemistry*, vol. 279, no. 34, pp. 35583–35594, 2004.

[36] Y. Kanda, M. Matsuda, K. Tawaramoto et al., “Effects of sulfonylurea drugs on adiponectin production from 3T3-L1 adipocytes: implication of different mechanism from pioglitazone,” *Diabetes Research and Clinical Practice*, vol. 81, no. 1, pp. 13–18, 2008.

[37] J. MacKellar, S. W. Cushman, and V. Periwal, “Differential effects of thiazolidinediones on adipocyte growth and recruitment in Zucker fatty rats,” *PLoS ONE*, vol. 4, no. 12, Article ID e8196, 2009.

[38] J. G. Kang, C.-Y. Park, S.-H. Ihm et al., “Mechanisms of adipose tissue redistribution with rosiglitazone treatment in various adipose depots,” *Metabolism*, vol. 59, no. 1, pp. 46–53, 2010.

[39] A. Harte, P. McTernan, R. Chetty et al., “Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone,” *Circulation*, vol. 111, no. 15, pp. 1954–1961, 2005.

[40] A. Saiki, M. Ohira, K. Endo et al., “Pioglitazone decreases plasma angiotensin II concentration in type 2 diabetes,” *Journal of Atherosclerosis and Thrombosis*, vol. 17, no. 6, pp. 651–657, 2010.